In addition, 92R mAb also increased survival in xenotransplanted animals carrying primary CCR9+ T cell leukemias and decreased the number of tumor-carrying animals, and their tumor size, on subcutaneous non-hematopoietic xenotransplants expressing CCR9. This evidence concerns the gene CCR9 and T-cell leukemia.